473299-53-5Relevant academic research and scientific papers
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes
Liu, Ping,Hu, Zhiyong,Dubois, Byron G.,Moyes, Christopher R.,Hunter, David N.,Zhu, Cheng,Kar, Nam Fung,Zhu, Yuping,Garfunkle, Joie,Kang, Ling,Chicchi, Gary,Ehrhardt, Anka,Woods, Andrea,Seo, Toru,Woods, Morgan,Van Heek, Margaret,Dingley, Karen H.,Pang, Jianmei,Salituro, Gino M.,Powell, Joyce,Terebetski, Jenna L.,Hornak, Viktor,Campeau, Louis-Charles,Lamberson, Joe,Ujjainwalla, Fez,Miller, Michael,Stamford, Andrew,Wood, Harold B.,Kowalski, Timothy,Nargund, Ravi P.,Edmondson, Scott D.
supporting information, p. 936 - 941 (2015/08/24)
We report herein the design and synthesis of a series of potent and selective GPR119 agonists. Our objective was to develop a GPR119 agonist with properties that were suitable for fixed-dose combination with a DPP4 inhibitor. Starting from a phenoxy analo
SUBSTITUTED CYCLOPROPYL COMPOUNDS
-
Page/Page column 47; 48; 50, (2014/04/17)
Substituted cyclopropyl piperidinyl compounds and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-1 19. Pharmaceutical compositions and methods of treatment are also included.
SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT
-
Page/Page column 53, (2013/02/28)
Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled rece
